drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00938 | DB11853 | 455 | 230 | [
"DDInter1635",
"DDInter1577"
] | Salmeterol | Relugolix | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
455,
24,
230
]
],
[
[
455,
24,
129
],
[
129,
23,
230
]
],
[
[
455,
24,
480
],
[
480,
24,
230
]
],
[
[
455,
63,
79
],
[
79,
24,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formo... |
DB00238 | DB01254 | 188 | 1,213 | [
"DDInter1285",
"DDInter484"
] | Nevirapine | Dasatinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
188,
24,
1213
]
],
[
[
188,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
188,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
188,
24,
1135
],
[
1135,... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Nevirapine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases whe... |
DB00284 | DB00774 | 1,647 | 1,577 | [
"DDInter11",
"DDInter889"
] | Acarbose | Hydroflumethiazide | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
1647,
24,
1577
]
],
[
[
1647,
24,
359
],
[
359,
40,
1577
]
],
[
[
1647,
24,
504
],
[
504,
1,
1577
]
],
[
[
1647,
21,
28826
],
[
28826,... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) re... |
DB00356 | DB11130 | 1,315 | 407 | [
"DDInter366",
"DDInter1344"
] | Chlorzoxazone | Opium | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1315,
24,
407
]
],
[
[
1315,
24,
662
],
[
662,
24,
407
]
],
[
[
1315,
63,
1648
],
[
1648,
24,
407
]
],
[
[
1315,
64,
475
],
[
475,
... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin an... |
DB05773 | DB06754 | 1,047 | 707 | [
"DDInter1848",
"DDInter471"
] | Trastuzumab emtansine | Danaparoid | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
1047,
25,
707
]
],
[
[
1047,
24,
41
],
[
41,
63,
707
]
],
[
[
1047,
63,
901
],
[
901,
24,
707
]
],
[
[
1047,
24,
643
],
[
643,
2... | [
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when ... |
DB08901 | DB11901 | 1,468 | 913 | [
"DDInter1492",
"DDInter107"
] | Ponatinib | Apalutamide | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1468,
24,
913
]
],
[
[
1468,
63,
112
],
[
112,
23,
913
]
],
[
[
1468,
24,
110
],
[
110,
62,
913
]
],
[
[
1468,
64,
279
],
[
279,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedoti... |
DB01324 | DB06655 | 178 | 5 | [
"DDInter1490",
"DDInter1077"
] | Polythiazide | Liraglutide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
178,
24,
5
]
],
[
[
178,
63,
870
],
[
870,
24,
5
]
],
[
[
178,
24,
1019
],
[
1019,
63,
5
]
],
[
[
178,
1,
1014
],
[
1014,
24,
... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]... | Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Deflaz... |
DB01114 | DB08897 | 272 | 1,429 | [
"DDInter362",
"DDInter22"
] | Chlorpheniramine | Aclidinium | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
272,
24,
1429
]
],
[
[
272,
63,
352
],
[
352,
24,
1429
]
],
[
[
272,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
272,
21,
28817
],
[
28817,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
]... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate a... |
DB00710 | DB12865 | 1,199 | 922 | [
"DDInter897",
"DDInter688"
] | Ibandronate | Etelcalcetide | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. | Major | 2 | [
[
[
1199,
25,
922
]
],
[
[
1199,
24,
485
],
[
485,
25,
922
]
],
[
[
1199,
40,
1485
],
[
1485,
25,
922
]
],
[
[
1199,
63,
589
],
[
589,
... | [
[
[
"Ibandronate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etelcalcetide"
]
],
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pent... | Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Etelcalcetide
Ibandronate (Compound) resembles Alendronic acid (Compound) and Alendronic acid may lead to a major life threatening inte... |
DB00405 | DB00754 | 128 | 157 | [
"DDInter517",
"DDInter696"
] | Dexbrompheniramine | Ethotoin | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
128,
24,
157
]
],
[
[
128,
24,
759
],
[
759,
40,
157
]
],
[
[
128,
24,
499
],
[
499,
1,
157
]
],
[
[
128,
18,
15501
],
[
15501,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide and Phensuximide (Compound) resembles Ethoto... |
DB00106 | DB08903 | 618 | 996 | [
"DDInter4",
"DDInter170"
] | Abarelix | Bedaquiline | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
618,
25,
996
]
],
[
[
618,
23,
112
],
[
112,
23,
996
]
],
[
[
618,
24,
355
],
[
355,
24,
996
]
],
[
[
618,
24,
144
],
[
144,
63,... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulos... |
DB00056 | DB06168 | 816 | 1,531 | [
"DDInter814",
"DDInter281"
] | Gemtuzumab ozogamicin | Canakinumab | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
816,
24,
1531
]
],
[
[
816,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
816,
24,
599
],
[
599,
24,
1531
]
],
[
[
816,
63,
305
],
[
305,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tube... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Gemtuzumab ozogamicin may cause a moderate i... |
DB00640 | DB01254 | 1,585 | 1,213 | [
"DDInter31",
"DDInter484"
] | Adenosine | Dasatinib | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1585,
24,
1213
]
],
[
[
1585,
18,
10780
],
[
10780,
57,
1213
]
],
[
[
1585,
21,
28743
],
[
28743,
60,
1213
]
],
[
[
1585,
24,
1133
],
[
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Adenosine",
"{u} (Compound) downregulates {v} (Gene)",
"CCNB2"
],
[
"CCNB2",
"{u} (Gene) is downregulated by {v} (... | Adenosine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Dasatinib (Compound)
Adenosine (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Dasatinib (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases when t... |
DB01030 | DB11757 | 869 | 960 | [
"DDInter1835",
"DDInter994"
] | Topotecan | Istradefylline | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Moderate | 1 | [
[
[
869,
24,
960
]
],
[
[
869,
24,
77
],
[
77,
24,
960
]
],
[
[
869,
63,
134
],
[
134,
24,
960
]
],
[
[
869,
24,
971
],
[
971,
63,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vin... |
DB01155 | DB01229 | 872 | 973 | [
"DDInter813",
"DDInter1378"
] | Gemifloxacin | Paclitaxel (protein-bound) | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Minor | 0 | [
[
[
872,
23,
973
]
],
[
[
872,
21,
30098
],
[
30098,
60,
973
]
],
[
[
872,
1,
945
],
[
945,
23,
973
]
],
[
[
872,
40,
1467
],
[
1467,
... | [
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Swelling face"
],
[
"Swelling face",
"{u} (Side Effec... | Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Gemifloxacin (Compound) causes Swelling face (Side Effect) and Swelling face (Side Effect) is caused by Paclitaxel (Compound)
Gemifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a minor... |
DB00346 | DB06616 | 472 | 594 | [
"DDInter44",
"DDInter224"
] | Alfuzosin | Bosutinib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
472,
24,
594
]
],
[
[
472,
6,
8374
],
[
8374,
45,
594
]
],
[
[
472,
21,
29231
],
[
29231,
60,
594
]
],
[
[
472,
23,
112
],
[
112,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Alfuzosin (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazol... |
DB00700 | DB09038 | 312 | 1,450 | [
"DDInter656",
"DDInter636"
] | Eplerenone | Empagliflozin | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
312,
24,
1450
]
],
[
[
312,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
312,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
312,
74,
870
],
[
870,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Methylpredniso... |
DB01069 | DB12825 | 401 | 1,375 | [
"DDInter1533",
"DDInter1032"
] | Promethazine | Lefamulin | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
401,
25,
1375
]
],
[
[
401,
62,
112
],
[
112,
23,
1375
]
],
[
[
401,
24,
1532
],
[
1532,
24,
1375
]
],
[
[
401,
63,
530
],
[
530,
... | [
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and I... |
DB01075 | DB06691 | 1,376 | 849 | [
"DDInter569",
"DDInter1155"
] | Diphenhydramine | Mepyramine | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1376,
24,
849
]
],
[
[
1376,
40,
11244
],
[
11244,
1,
849
]
],
[
[
1376,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1376,
35,
272
],
[
272,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Pheniramine"
],
[
"Pheniramine",
"{u} (Compou... | Diphenhydramine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Mepyramine (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB06209 | DB12364 | 256 | 1,421 | [
"DDInter1508",
"DDInter200"
] | Prasugrel | Betrixaban | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
256,
25,
1421
]
],
[
[
256,
23,
297
],
[
297,
23,
1421
]
],
[
[
256,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
256,
24,
992
],
[
992,
... | [
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} ... | Prasugrel may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor... |
DB00978 | DB11113 | 739 | 657 | [
"DDInter1084",
"DDInter307"
] | Lomefloxacin | Castor oil | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
739,
24,
657
]
],
[
[
739,
24,
927
],
[
927,
63,
657
]
],
[
[
739,
24,
1491
],
[
1491,
24,
657
]
],
[
[
739,
64,
891
],
[
891,
2... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and... |
DB00252 | DB01390 | 362 | 1,117 | [
"DDInter1460",
"DDInter1683"
] | Phenytoin | Sodium bicarbonate | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
362,
24,
1117
]
],
[
[
362,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
362,
24,
1220
],
[
1220,
23,
1117
]
],
[
[
362,
63,
1018
],
[
1018... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is ca... | Phenytoin (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with S... |
DB00996 | DB01233 | 1,198 | 1,311 | [
"DDInter791",
"DDInter1197"
] | Gabapentin | Metoclopramide | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1198,
24,
1311
]
],
[
[
1198,
5,
11610
],
[
11610,
49,
1311
]
],
[
[
1198,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1198,
63,
1010
],
[
... | [
[
[
"Gabapentin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Gabapentin",
"{u} (Compound) treats {v} (Disease)",
"migraine"
],
[
"migraine",
"{u} (Disease) is palliated ... | Gabapentin (Compound) treats migraine (Disease) and migraine (Disease) is palliated by Metoclopramide (Compound)
Gabapentin (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Gabapentin may cause a moderate interaction that could exacerbate diseases when taken... |
DB00598 | DB06704 | 1,523 | 247 | [
"DDInter1013",
"DDInter952"
] | Labetalol | Iobenguane (I-131) | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
1523,
37,
247
]
],
[
[
1523,
21,
28787
],
[
28787,
60,
247
]
],
[
[
1523,
24,
820
],
[
820,
24,
247
]
],
[
[
1523,
63,
999
],
[
999,
... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Labetalol may lead to a major life threatening interaction when taken with Iobenguane
Labetalol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Labetalol ma... |
DB00562 | DB00771 | 1,014 | 262 | [
"DDInter188",
"DDInter397"
] | Benzthiazide | Clidinium | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Minor | 0 | [
[
[
1014,
23,
262
]
],
[
[
1014,
23,
1511
],
[
1511,
63,
262
]
],
[
[
1014,
1,
323
],
[
323,
23,
262
]
],
[
[
1014,
40,
504
],
[
504,
... | [
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clidinium"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate"
],
[
... | Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Benzthiazide (Compound) resembles Bendroflumethiazide (Compound) and Bendroflumethiazide may cause a minor inte... |
DB09241 | DB11732 | 1,629 | 1,097 | [
"DDInter1186",
"DDInter1027"
] | Methylene blue | Lasmiditan | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Major | 2 | [
[
[
1629,
25,
1097
]
],
[
[
1629,
64,
475
],
[
475,
24,
1097
]
],
[
[
1629,
63,
1311
],
[
1311,
24,
1097
]
],
[
[
1629,
25,
407
],
[
407,
... | [
[
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lasmiditan"
]
],
[
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{... | Methylene blue may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramid... |
DB00951 | DB06626 | 1,072 | 263 | [
"DDInter986",
"DDInter147"
] | Isoniazid | Axitinib | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
1072,
24,
263
]
],
[
[
1072,
23,
115
],
[
115,
62,
263
]
],
[
[
1072,
63,
322
],
[
322,
24,
263
]
],
[
[
1072,
24,
392
],
[
392,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
],
[
... | Isoniazid may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Axitinib
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin an... |
DB00241 | DB00434 | 288 | 13 | [
"DDInter257",
"DDInter459"
] | Butalbital | Cyproheptadine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
288,
24,
13
]
],
[
[
288,
24,
104
],
[
104,
63,
13
]
],
[
[
288,
10,
11610
],
[
11610,
49,
13
]
],
[
[
288,
24,
128
],
[
128,
24... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Butalbital (Compound) palliates migraine (Disease) and migraine (Disease) is palliated by Cyproheptadine... |
DB00261 | DB09082 | 702 | 659 | [
"DDInter93",
"DDInter1934"
] | Anagrelide | Vilanterol | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
702,
24,
659
]
],
[
[
702,
64,
1570
],
[
1570,
24,
659
]
],
[
[
702,
25,
927
],
[
927,
63,
659
]
],
[
[
702,
25,
1069
],
[
1069,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azithromycin"
],
[
"Azithrom... | Anagrelide may lead to a major life threatening interaction when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Anagrelide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderat... |
DB00872 | DB08916 | 1,080 | 26 | [
"DDInter438",
"DDInter32"
] | Conivaptan | Afatinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
1080,
24,
26
]
],
[
[
1080,
63,
883
],
[
883,
40,
26
]
],
[
[
1080,
21,
28809
],
[
28809,
60,
26
]
],
[
[
1080,
25,
124
],
[
124,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Conivaptan (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)
Conivaptan may lead to a major life threatening in... |
DB00060 | DB14783 | 912 | 287 | [
"DDInter947",
"DDInter574"
] | Interferon beta-1a | Diroximel fumarate | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
912,
24,
287
]
],
[
[
912,
24,
1101
],
[
1101,
24,
287
]
],
[
[
912,
63,
1560
],
[
1560,
24,
287
]
],
[
[
912,
25,
1510
],
[
1510,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bex... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00652 | DB01612 | 234 | 1,637 | [
"DDInter1421",
"DDInter92"
] | Pentazocine | Amyl Nitrite | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
234,
24,
1637
]
],
[
[
234,
64,
475
],
[
475,
24,
1637
]
],
[
[
234,
24,
401
],
[
401,
24,
1637
]
],
[
[
234,
25,
593
],
[
593,
... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Pentazocine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine... | Pentazocine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may ca... |
DB00529 | DB01249 | 789 | 258 | [
"DDInter779",
"DDInter958"
] | Foscarnet | Iodixanol | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Major | 2 | [
[
[
789,
25,
258
]
],
[
[
789,
25,
497
],
[
497,
1,
258
]
],
[
[
789,
21,
28757
],
[
28757,
60,
258
]
],
[
[
789,
24,
712
],
[
712,
... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} (Compound)... | Foscarnet may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Foscarnet (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Iodixanol (Compound)
Foscarnet may cause a moderate interaction that could exacerbate dise... |
DB00975 | DB01166 | 1,317 | 477 | [
"DDInter573",
"DDInter379"
] | Dipyridamole | Cilostazol | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1317,
24,
477
]
],
[
[
1317,
6,
9977
],
[
9977,
45,
477
]
],
[
[
1317,
18,
2201
],
[
2201,
57,
477
]
],
[
[
1317,
21,
28919
],
[
28919... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Dipyridamole",
"{u} (Compound) binds {v} (Gene)",
"PDE3A"
],
[
"PDE3A",
"{u} (Gene) is bound by {v} (Compound)... | Dipyridamole (Compound) binds PDE3A (Gene) and PDE3A (Gene) is bound by Cilostazol (Compound)
Dipyridamole (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Cilostazol (Compound)
Dipyridamole (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Comp... |
DB00063 | DB05773 | 366 | 1,047 | [
"DDInter659",
"DDInter1848"
] | Eptifibatide | Trastuzumab emtansine | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Major | 2 | [
[
[
366,
25,
1047
]
],
[
[
366,
24,
848
],
[
848,
24,
1047
]
],
[
[
366,
24,
643
],
[
643,
63,
1047
]
],
[
[
366,
25,
1018
],
[
1018,
... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Desvenla... |
DB00444 | DB00467 | 63 | 1,467 | [
"DDInter1765",
"DDInter644"
] | Teniposide | Enoxacin | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Minor | 0 | [
[
[
63,
23,
1467
]
],
[
[
63,
23,
1539
],
[
1539,
40,
1467
]
],
[
[
63,
23,
1299
],
[
1299,
1,
1467
]
],
[
[
63,
62,
1176
],
[
1176,
... | [
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
]
],
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
],
[
"Of... | Teniposide may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) resembles Enoxacin (Compound)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin (Compound) resembles Enoxacin (Compound)
Teni... |
DB01229 | DB12095 | 973 | 179 | [
"DDInter1378",
"DDInter1760"
] | Paclitaxel (protein-bound) | Telotristat ethyl | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
973,
24,
179
]
],
[
[
973,
63,
79
],
[
79,
24,
179
]
],
[
[
973,
24,
310
],
[
310,
24,
179
]
],
[
[
973,
24,
283
],
[
283,
63,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethy... |
DB00279 | DB06655 | 1,152 | 5 | [
"DDInter1074",
"DDInter1077"
] | Liothyronine | Liraglutide | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1152,
24,
5
]
],
[
[
1152,
24,
1252
],
[
1252,
23,
5
]
],
[
[
1152,
24,
1142
],
[
1142,
24,
5
]
],
[
[
1152,
24,
192
],
[
192,
6... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat ma... |
DB04835 | DB08880 | 1,655 | 1,510 | [
"DDInter1125",
"DDInter1771"
] | Maraviroc | Teriflunomide | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1655,
25,
1510
]
],
[
[
1655,
25,
129
],
[
129,
63,
1510
]
],
[
[
1655,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
1655,
63,
1061
],
[
1061... | [
[
[
"Maraviroc",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Maraviroc",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"... | Maraviroc may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cau... |
DB00047 | DB00734 | 176 | 1,664 | [
"DDInter932",
"DDInter1605"
] | Insulin glargine | Risperidone | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
176,
24,
1664
]
],
[
[
176,
24,
924
],
[
924,
40,
1664
]
],
[
[
176,
24,
1616
],
[
1616,
63,
1664
]
],
[
[
176,
24,
999
],
[
999,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interacti... |
DB00960 | DB08884 | 887 | 796 | [
"DDInter1471",
"DDInter800"
] | Pindolol | Gadoxetic acid | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing ionic linear contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up ... | Moderate | 1 | [
[
[
887,
24,
796
]
],
[
[
887,
63,
457
],
[
457,
1,
796
]
],
[
[
887,
24,
1106
],
[
1106,
1,
796
]
],
[
[
887,
21,
28841
],
[
28841,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoxetic acid"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],
[
... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadoxetic acid (Compound)
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) resemb... |
DB00031 | DB06822 | 20 | 802 | [
"DDInter1764",
"DDInter1812"
] | Tenecteplase | Tinzaparin | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Major | 2 | [
[
[
20,
25,
802
]
],
[
[
20,
23,
944
],
[
944,
62,
802
]
],
[
[
20,
24,
222
],
[
222,
24,
802
]
],
[
[
20,
24,
1427
],
[
1427,
63,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile... | Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutra... |
DB00005 | DB01174 | 1,057 | 697 | [
"DDInter687",
"DDInter1442"
] | Etanercept | Phenobarbital | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
1057,
24,
697
]
],
[
[
1057,
24,
759
],
[
759,
1,
697
]
],
[
[
1057,
25,
37
],
[
37,
62,
697
]
],
[
[
1057,
25,
450
],
[
450,
23... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Etanercept may lead to a major life threatening interaction when taken with Lomustine and Lomustine may cause a minor interaction that can limit clinical effec... |
DB00477 | DB14568 | 216 | 982 | [
"DDInter363",
"DDInter1000"
] | Chlorpromazine | Ivosidenib | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
216,
25,
982
]
],
[
[
216,
23,
112
],
[
112,
23,
982
]
],
[
[
216,
24,
543
],
[
543,
24,
982
]
],
[
[
216,
25,
11
],
[
11,
25,
... | [
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"M... | Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide ... |
DB00106 | DB06288 | 618 | 607 | [
"DDInter4",
"DDInter77"
] | Abarelix | Amisulpride | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
618,
25,
607
]
],
[
[
618,
23,
112
],
[
112,
23,
607
]
],
[
[
618,
24,
1559
],
[
1559,
24,
607
]
],
[
[
618,
24,
1383
],
[
1383,
... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amisulpride
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotid... |
DB09122 | DB13985 | 1,613 | 546 | [
"DDInter1409",
"DDInter1108"
] | Peginterferon beta-1a | Lutetium Lu 177 dotatate | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
1613,
24,
546
]
],
[
[
1613,
63,
50
],
[
50,
24,
546
]
],
[
[
1613,
64,
1377
],
[
1377,
25,
546
]
],
[
[
1613,
63,
581
],
[
581,
... | [
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Peginterferon beta-1a may lead to a major life threatening interaction when taken... |
DB00619 | DB14881 | 1,419 | 180 | [
"DDInter909",
"DDInter1329"
] | Imatinib | Oliceridine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
1419,
25,
180
]
],
[
[
1419,
24,
401
],
[
401,
24,
180
]
],
[
[
1419,
63,
1184
],
[
1184,
24,
180
]
],
[
[
1419,
25,
484
],
[
484,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazin... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinr... |
DB11828 | DB15328 | 1,406 | 829 | [
"DDInter1281",
"DDInter1896"
] | Neratinib | Ubrogepant | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1406,
24,
829
]
],
[
[
1406,
63,
578
],
[
578,
24,
829
]
],
[
[
1406,
64,
1593
],
[
1593,
24,
829
]
],
[
[
1406,
24,
1619
],
[
1619,
... | [
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
... | Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Neratinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a ... |
DB00081 | DB11601 | 273 | 1,270 | [
"DDInter1838",
"DDInter1889"
] | Tositumomab | Tuberculin purified protein derivative | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
273,
24,
1270
]
],
[
[
273,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
273,
25,
1064
],
[
1064,
24,
1270
]
],
[
[
273,
25,
1259
],
[
1259,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Tositumomab may lead to a major life threatening interaction when taken with Clad... |
DB00108 | DB00762 | 1,066 | 613 | [
"DDInter1268",
"DDInter973"
] | Natalizumab | Irinotecan | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Major | 2 | [
[
[
1066,
25,
613
]
],
[
[
1066,
25,
869
],
[
869,
63,
613
]
],
[
[
1066,
64,
599
],
[
599,
24,
613
]
],
[
[
1066,
25,
1555
],
[
1555,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Irinotecan"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} m... | Natalizumab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Natalizumab may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate in... |
DB06273 | DB15965 | 980 | 1,330 | [
"DDInter1824",
"DDInter1270"
] | Tocilizumab | Naxitamab | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
980,
24,
1330
]
],
[
[
980,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
980,
63,
14
],
[
14,
24,
1330
]
],
[
[
980,
25,
259
],
[
259,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Tocilizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[... | Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and... |
DB06674 | DB08868 | 908 | 1,011 | [
"DDInter837",
"DDInter737"
] | Golimumab | Fingolimod | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
908,
25,
1011
]
],
[
[
908,
63,
112
],
[
112,
23,
1011
]
],
[
[
908,
24,
748
],
[
748,
63,
1011
]
],
[
[
908,
63,
1136
],
[
1136,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and... |
DB00852 | DB04861 | 1,445 | 1,592 | [
"DDInter1545",
"DDInter1271"
] | Pseudoephedrine | Nebivolol | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
1445,
24,
1592
]
],
[
[
1445,
6,
3576
],
[
3576,
45,
1592
]
],
[
[
1445,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
1445,
24,
1450
],
[
1... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is bound by {v} (Comp... | Pseudoephedrine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Nebivolol (Compound)
Pseudoephedrine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflo... |
DB00872 | DB11730 | 1,080 | 351 | [
"DDInter438",
"DDInter1588"
] | Conivaptan | Ribociclib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1080,
25,
351
]
],
[
[
1080,
24,
466
],
[
466,
62,
351
]
],
[
[
1080,
24,
222
],
[
222,
23,
351
]
],
[
[
1080,
25,
283
],
[
283,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sib... |
DB08931 | DB09481 | 947 | 460 | [
"DDInter1600",
"DDInter1113"
] | Riociguat | Magnesium carbonate | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
947,
24,
460
]
],
[
[
947,
63,
1195
],
[
1195,
24,
460
]
],
[
[
947,
24,
286
],
[
286,
24,
460
]
],
[
[
947,
63,
1195
],
[
1195,
... | [
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
... | Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydrox... |
DB00197 | DB04865 | 1,324 | 4 | [
"DDInter1881",
"DDInter1335"
] | Troglitazone | Omacetaxine mepesuccinate | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
1324,
24,
4
]
],
[
[
1324,
24,
10
],
[
10,
24,
4
]
],
[
[
1324,
24,
1250
],
[
1250,
63,
4
]
],
[
[
1324,
63,
305
],
[
305,
24,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pazopani... |
DB00865 | DB01142 | 939 | 1,264 | [
"DDInter187",
"DDInter593"
] | Benzphetamine | Doxepin | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
939,
24,
1264
]
],
[
[
939,
40,
508
],
[
508,
24,
1264
]
],
[
[
939,
24,
401
],
[
401,
24,
1264
]
],
[
[
939,
1,
832
],
[
832,
2... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a modera... | Benzphetamine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that ... |
DB00783 | DB01132 | 1,438 | 1,130 | [
"DDInter679",
"DDInter1472"
] | Estradiol | Pioglitazone | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1438,
24,
1130
]
],
[
[
1438,
6,
6017
],
[
6017,
45,
1130
]
],
[
[
1438,
7,
6444
],
[
6444,
46,
1130
]
],
[
[
1438,
21,
28661
],
[
286... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",... | Estradiol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pioglitazone (Compound)
Estradiol (Compound) upregulates TIAM1 (Gene) and TIAM1 (Gene) is upregulated by Pioglitazone (Compound)
Estradiol (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by... |
DB00285 | DB00470 | 1,100 | 530 | [
"DDInter1927",
"DDInter601"
] | Venlafaxine | Dronabinol | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
1100,
24,
530
]
],
[
[
1100,
24,
1614
],
[
1614,
40,
530
]
],
[
[
1100,
6,
6017
],
[
6017,
45,
530
]
],
[
[
1100,
21,
29226
],
[
29226... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Venlafaxine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dronabinol (Compound)
Venlafaxine (Compound) causes Sinusitis (Side Effect) and Sinusitis ... |
DB05239 | DB11817 | 866 | 1,259 | [
"DDInter425",
"DDInter165"
] | Cobimetinib | Baricitinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
866,
25,
1259
]
],
[
[
866,
24,
949
],
[
949,
24,
1259
]
],
[
[
866,
63,
563
],
[
563,
24,
1259
]
],
[
[
866,
24,
1129
],
[
1129,
... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (form... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Cobimetini... |
DB01254 | DB08865 | 1,213 | 1,593 | [
"DDInter484",
"DDInter448"
] | Dasatinib | Crizotinib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1213,
25,
1593
]
],
[
[
1213,
6,
5304
],
[
5304,
45,
1593
]
],
[
[
1213,
34,
3415
],
[
3415,
45,
1593
]
],
[
[
1213,
18,
2663
],
[
266... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Dasatinib",
"{u} (Compound) binds {v} (Gene)",
"ABL2"
],
[
"ABL2",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
... | Dasatinib (Compound) binds ABL2 (Gene) and ABL2 (Gene) is bound by Crizotinib (Compound)
Dasatinib (Compound) binds EPHA3 (Gene) and Dasatinib (Compound) upregulates EPHA3 (Gene) and EPHA3 (Gene) is bound by Crizotinib (Compound)
Dasatinib (Compound) downregulates AXL (Gene) and AXL (Gene) is bound by Crizotinib (Compo... |
DB00836 | DB00844 | 543 | 314 | [
"DDInter1088",
"DDInter1257"
] | Loperamide | Nalbuphine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
543,
24,
314
]
],
[
[
543,
63,
828
],
[
828,
40,
314
]
],
[
[
543,
63,
421
],
[
421,
1,
314
]
],
[
[
543,
63,
475
],
[
475,
25,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Compou... |
DB01285 | DB06643 | 708 | 1,136 | [
"DDInter445",
"DDInter500"
] | Corticotropin | Denosumab | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
708,
24,
1136
]
],
[
[
708,
63,
1648
],
[
1648,
24,
1136
]
],
[
[
708,
64,
1377
],
[
1377,
24,
1136
]
],
[
[
708,
25,
1510
],
[
1510,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Corticotropin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide m... |
DB11967 | DB12332 | 710 | 1,619 | [
"DDInter210",
"DDInter1626"
] | Binimetinib | Rucaparib | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
710,
24,
1619
]
],
[
[
710,
63,
307
],
[
307,
23,
1619
]
],
[
[
710,
63,
556
],
[
556,
24,
1619
]
],
[
[
710,
64,
1213
],
[
1213,
... | [
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valpro... |
DB00015 | DB00461 | 582 | 598 | [
"DDInter1585",
"DDInter1254"
] | Reteplase | Nabumetone | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Moderate | 1 | [
[
[
582,
24,
598
]
],
[
[
582,
25,
366
],
[
366,
24,
598
]
],
[
[
582,
24,
1512
],
[
1512,
63,
598
]
],
[
[
582,
25,
936
],
[
936,
6... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabumetone"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifibati... | Reteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may caus... |
DB00005 | DB11003 | 1,057 | 748 | [
"DDInter687",
"DDInter100"
] | Etanercept | Anthrax vaccine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1057,
24,
748
]
],
[
[
1057,
25,
322
],
[
322,
24,
748
]
],
[
[
1057,
25,
564
],
[
564,
63,
748
]
],
[
[
1057,
64,
669
],
[
669,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epiru... | Etanercept may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Etanercept may lead to a major life threatening interaction when taken with Abemaciclib and Abemaciclib may cause a modera... |
DB00063 | DB00176 | 366 | 529 | [
"DDInter659",
"DDInter770"
] | Eptifibatide | Fluvoxamine | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Moderate | 1 | [
[
[
366,
24,
529
]
],
[
[
366,
64,
20
],
[
20,
24,
529
]
],
[
[
366,
24,
1274
],
[
1274,
63,
529
]
],
[
[
366,
25,
1172
],
[
1172,
2... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Ten... | Eptifibatide may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprof... |
DB00295 | DB01452 | 475 | 993 | [
"DDInter1244",
"DDInter532"
] | Morphine | Diamorphine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Major | 2 | [
[
[
475,
25,
993
]
],
[
[
475,
40,
1044
],
[
1044,
40,
993
]
],
[
[
475,
25,
421
],
[
421,
40,
993
]
],
[
[
475,
40,
11240
],
[
11240,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diamorphine"
]
],
[
[
"Morphine",
"{u} (Compound) resembles {v} (Compound)",
"Codeine"
],
[
"Codeine",
"{u} (Compound) resembles {v} (Compound)",
... | Morphine (Compound) resembles Codeine (Compound) and Codeine (Compound) resembles Diamorphine (Compound)
Morphine may lead to a major life threatening interaction when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Morphine (Compound) resembles Ethylmorphine (Compound) and Ethylm... |
DB00514 | DB00679 | 506 | 684 | [
"DDInter527",
"DDInter1796"
] | Dextromethorphan | Thioridazine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Moderate | 1 | [
[
[
506,
24,
684
]
],
[
[
506,
24,
146
],
[
146,
40,
684
]
],
[
[
506,
63,
216
],
[
216,
1,
684
]
],
[
[
506,
25,
9
],
[
9,
1,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Thioridazine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resemb... |
DB00238 | DB00631 | 188 | 372 | [
"DDInter1285",
"DDInter405"
] | Nevirapine | Clofarabine | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
188,
24,
372
]
],
[
[
188,
21,
29402
],
[
29402,
60,
372
]
],
[
[
188,
24,
927
],
[
927,
63,
372
]
],
[
[
188,
63,
1560
],
[
1560,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Nevirapine",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatobiliary disease"
],
[
"Hepatobiliary disease",
"... | Nevirapine (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Clofarabine (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate disea... |
DB00350 | DB04844 | 1,214 | 843 | [
"DDInter1226",
"DDInter1778"
] | Minoxidil | Tetrabenazine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1214,
24,
843
]
],
[
[
1214,
24,
1376
],
[
1376,
24,
843
]
],
[
[
1214,
63,
475
],
[
475,
24,
843
]
],
[
[
1214,
24,
849
],
[
849,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Morphine a... |
DB01023 | DB05679 | 409 | 1,683 | [
"DDInter716",
"DDInter1907"
] | Felodipine | Ustekinumab | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
409,
24,
1683
]
],
[
[
409,
24,
1042
],
[
1042,
24,
1683
]
],
[
[
409,
24,
1093
],
[
1093,
63,
1683
]
],
[
[
409,
40,
1428
],
[
1428,
... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
... | Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab a... |
DB05812 | DB08827 | 1,374 | 990 | [
"DDInter8",
"DDInter1085"
] | Abiraterone | Lomitapide | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1374,
25,
990
]
],
[
[
1374,
62,
1080
],
[
1080,
1,
990
]
],
[
[
1374,
6,
8374
],
[
8374,
45,
990
]
],
[
[
1374,
21,
28701
],
[
28701,... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Conivaptan"
],
[
"Conivaptan... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Abiraterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Abiraterone (Compound) causes Discomfort (Side Effect) and Discomf... |
DB00637 | DB06176 | 1,557 | 1,342 | [
"DDInter128",
"DDInter1616"
] | Astemizole | Romidepsin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1557,
24,
1342
]
],
[
[
1557,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
1557,
24,
956
],
[
956,
24,
1342
]
],
[
[
1557,
24,
1616
],
[
1616... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin a... |
DB06403 | DB12267 | 1,204 | 1,476 | [
"DDInter62",
"DDInter233"
] | Ambrisentan | Brigatinib | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the Un... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1204,
24,
1476
]
],
[
[
1204,
63,
79
],
[
79,
24,
1476
]
],
[
[
1204,
24,
1456
],
[
1456,
24,
1476
]
],
[
[
1204,
62,
86
],
[
86,
... | [
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Veneto... |
DB00278 | DB00814 | 291 | 1,171 | [
"DDInter117",
"DDInter1143"
] | Argatroban | Meloxicam | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
291,
24,
1171
]
],
[
[
291,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
291,
6,
8374
],
[
8374,
45,
1171
]
],
[
[
291,
21,
28695
],
[
28695,... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Argatroban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Meloxicam (Compound)
Argatroban (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side... |
DB01364 | DB06203 | 22 | 1,002 | [
"DDInter650",
"DDInter51"
] | Ephedrine | Alogliptin | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
22,
24,
1002
]
],
[
[
22,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
22,
21,
28787
],
[
28787,
60,
1002
]
],
[
[
22,
63,
401
],
[
401,
... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Ephedrine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Alogliptin (Compound)
Ephedrine may cause a moderate interaction... |
DB00531 | DB11988 | 450 | 270 | [
"DDInter456",
"DDInter1321"
] | Cyclophosphamide | Ocrelizumab | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
450,
24,
270
]
],
[
[
450,
63,
1461
],
[
1461,
23,
270
]
],
[
[
450,
63,
134
],
[
134,
24,
270
]
],
[
[
450,
24,
713
],
[
713,
2... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine ... |
DB08904 | DB12159 | 375 | 12 | [
"DDInter342",
"DDInter609"
] | Certolizumab pegol | Dupilumab | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that indu... | Major | 2 | [
[
[
375,
25,
12
]
],
[
[
375,
62,
1461
],
[
1461,
23,
12
]
],
[
[
375,
23,
1114
],
[
1114,
23,
12
]
],
[
[
375,
63,
599
],
[
599,
24... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dupilumab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate a... |
DB00976 | DB09330 | 1,056 | 985 | [
"DDInter1758",
"DDInter1352"
] | Telithromycin | Osimertinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1056,
25,
985
]
],
[
[
1056,
63,
168
],
[
168,
23,
985
]
],
[
[
1056,
62,
112
],
[
112,
23,
985
]
],
[
[
1056,
25,
1478
],
[
1478,
... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bor... | Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB00712 | DB01124 | 1,274 | 1,411 | [
"DDInter763",
"DDInter1828"
] | Flurbiprofen | Tolbutamide | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1274,
24,
1411
]
],
[
[
1274,
24,
959
],
[
959,
40,
1411
]
],
[
[
1274,
23,
824
],
[
824,
24,
1411
]
],
[
[
1274,
63,
245
],
[
245,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Probenecid and Probenecid may cause a moderate interaction that coul... |
DB00026 | DB09570 | 1,184 | 1,480 | [
"DDInter94",
"DDInter1002"
] | Anakinra | Ixazomib | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
1184,
24,
1480
]
],
[
[
1184,
24,
987
],
[
987,
63,
1480
]
],
[
[
1184,
24,
453
],
[
453,
24,
1480
]
],
[
[
1184,
23,
1461
],
[
1461,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strai... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Anakinra may cause a moderate interaction ... |
DB00650 | DB01320 | 1,147 | 651 | [
"DDInter1041",
"DDInter783"
] | Leucovorin | Fosphenytoin | Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharma... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
1147,
24,
651
]
],
[
[
1147,
63,
362
],
[
362,
1,
651
]
],
[
[
1147,
21,
28784
],
[
28784,
60,
651
]
],
[
[
1147,
40,
356
],
[
356,
... | [
[
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Leucovorin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Leucovorin (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Fosphenytoin (Compound)
Leucovorin (Compound) resemb... |
DB00390 | DB13142 | 1,252 | 841 | [
"DDInter554",
"DDInter274"
] | Digoxin | Calcium glubionate anhydrous | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
1252,
24,
841
]
],
[
[
1252,
24,
1669
],
[
1669,
24,
841
]
],
[
[
1252,
1,
1482
],
[
1482,
24,
841
]
],
[
[
1252,
63,
1152
],
[
1152,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Digoxin (Compound) resembles Digitoxin (Compound) and Digitoxin may cause a moderate interactio... |
DB00295 | DB09128 | 475 | 1,241 | [
"DDInter1244",
"DDInter231"
] | Morphine | Brexpiprazole | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Major | 2 | [
[
[
475,
25,
1241
]
],
[
[
475,
24,
407
],
[
407,
63,
1241
]
],
[
[
475,
24,
543
],
[
543,
24,
1241
]
],
[
[
475,
63,
701
],
[
701,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may ca... |
DB00445 | DB00598 | 322 | 1,523 | [
"DDInter655",
"DDInter1013"
] | Epirubicin | Labetalol | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
322,
24,
1523
]
],
[
[
322,
24,
455
],
[
455,
64,
1523
]
],
[
[
322,
24,
1148
],
[
1148,
63,
1523
]
],
[
[
322,
24,
954
],
[
954,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Labetalol
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cau... |
DB06262 | DB06706 | 1,354 | 468 | [
"DDInter606",
"DDInter985"
] | Droxidopa | Isometheptene | Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a def... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
1354,
24,
468
]
],
[
[
1354,
6,
5214
],
[
5214,
45,
468
]
],
[
[
1354,
63,
480
],
[
480,
24,
468
]
],
[
[
1354,
24,
1629
],
[
1629,
... | [
[
[
"Droxidopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Droxidopa",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)"... | Droxidopa (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Isometheptene (Compound)
Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Droxidopa may ... |
DB00454 | DB01246 | 1,349 | 820 | [
"DDInter1150",
"DDInter45"
] | Meperidine | Alimemazine | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1349,
24,
820
]
],
[
[
1349,
24,
104
],
[
104,
40,
820
]
],
[
[
1349,
24,
401
],
[
401,
24,
820
]
],
[
[
1349,
24,
649
],
[
649,
... | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction t... |
DB00365 | DB00491 | 839 | 127 | [
"DDInter842",
"DDInter1217"
] | Grepafloxacin | Miglitol | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Moderate | 1 | [
[
[
839,
24,
127
]
],
[
[
839,
25,
1486
],
[
1486,
63,
127
]
],
[
[
839,
64,
245
],
[
245,
24,
127
]
],
[
[
839,
24,
688
],
[
688,
6... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
... | Grepafloxacin may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Miglitol
Grepafloxacin may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride may... |
DB00106 | DB00679 | 618 | 684 | [
"DDInter4",
"DDInter1796"
] | Abarelix | Thioridazine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Major | 2 | [
[
[
618,
25,
684
]
],
[
[
618,
24,
1237
],
[
1237,
40,
684
]
],
[
[
618,
24,
216
],
[
216,
1,
684
]
],
[
[
618,
23,
112
],
[
112,
62... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomiprami... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Thioridazine... |
DB01259 | DB01268 | 392 | 1,151 | [
"DDInter1024",
"DDInter1731"
] | Lapatinib | Sunitinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
392,
24,
1151
]
],
[
[
392,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
392,
7,
7161
],
[
7161,
46,
1151
]
],
[
[
392,
18,
6420
],
[
6420,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Lapatinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Lapatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Lapatinib (Compound) upregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Sunitinib (Compound)
Lapatinib (Compound) downregulates FOSL1 (Gene) and FOSL1 (Gene) is downregulated by Sunitinib (Compound)
Lapatinib (Compound)... |
DB11901 | DB15328 | 913 | 829 | [
"DDInter107",
"DDInter1896"
] | Apalutamide | Ubrogepant | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resi... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Major | 2 | [
[
[
913,
25,
829
]
],
[
[
913,
25,
1476
],
[
1476,
24,
829
]
],
[
[
913,
63,
1468
],
[
1468,
24,
829
]
],
[
[
913,
64,
578
],
[
578,
... | [
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ubrogepant"
]
],
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u}... | Apalutamide may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause ... |
DB11793 | DB14811 | 738 | 385 | [
"DDInter1297",
"DDInter979"
] | Niraparib | Isatuximab | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
738,
24,
385
]
],
[
[
738,
63,
1362
],
[
1362,
24,
385
]
],
[
[
738,
24,
270
],
[
270,
24,
385
]
],
[
[
738,
64,
908
],
[
908,
2... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab... |
DB00877 | DB11978 | 629 | 124 | [
"DDInter1678",
"DDInter822"
] | Sirolimus | Glasdegib | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
629,
24,
124
]
],
[
[
629,
24,
327
],
[
327,
24,
124
]
],
[
[
629,
25,
1079
],
[
1079,
24,
124
]
],
[
[
629,
63,
79
],
[
79,
24,... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Sirolimus may lead to a major life threatening interaction when taken with Telavancin and Telavancin may cause a m... |
DB00218 | DB09080 | 1,176 | 144 | [
"DDInter1247",
"DDInter1331"
] | Moxifloxacin | Olodaterol | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1176,
24,
144
]
],
[
[
1176,
1,
956
],
[
956,
24,
144
]
],
[
[
1176,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1176,
24,
543
],
[
543,
... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a m... | Moxifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Moxifloxacin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerba... |
DB00476 | DB03904 | 109 | 1,574 | [
"DDInter608",
"DDInter1903"
] | Duloxetine | Urea | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Moderate | 1 | [
[
[
109,
24,
1574
]
],
[
[
109,
63,
1314
],
[
1314,
24,
1574
]
],
[
[
109,
25,
497
],
[
497,
24,
1574
]
],
[
[
109,
23,
286
],
[
286,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Urea
Duloxetine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a modera... |
DB00374 | DB09075 | 1,061 | 498 | [
"DDInter1852",
"DDInter621"
] | Treprostinil | Edoxaban | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
1061,
25,
498
]
],
[
[
1061,
23,
944
],
[
944,
62,
498
]
],
[
[
1061,
24,
1004
],
[
1004,
63,
498
]
],
[
[
1061,
24,
41
],
[
41,
... | [
[
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phe... |
DB00881 | DB13620 | 954 | 948 | [
"DDInter1554",
"DDInter1499"
] | Quinapril | Potassium gluconate | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Major | 2 | [
[
[
954,
25,
948
]
],
[
[
954,
63,
176
],
[
176,
23,
948
]
],
[
[
954,
24,
1254
],
[
1254,
23,
948
]
],
[
[
954,
24,
848
],
[
848,
2... | [
[
[
"Quinapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Insu... |
DB00277 | DB14509 | 1,031 | 1,399 | [
"DDInter1791",
"DDInter1081"
] | Theophylline | Lithium carbonate | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1031,
24,
1399
]
],
[
[
1031,
63,
964
],
[
964,
23,
1399
]
],
[
[
1031,
24,
1545
],
[
1545,
23,
1399
]
],
[
[
1031,
24,
1674
],
[
1674... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracy... |
DB00577 | DB01250 | 1,295 | 712 | [
"DDInter1908",
"DDInter1334"
] | Valaciclovir | Olsalazine | Valaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline. Valacyclovir is the L-valine ester of aciclovir. It is a member o... | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
1295,
24,
712
]
],
[
[
1295,
24,
50
],
[
50,
40,
712
]
],
[
[
1295,
24,
485
],
[
485,
24,
712
]
],
[
[
1295,
1,
387
],
[
387,
24... | [
[
[
"Valaciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Valaciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
... | Valaciclovir may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Valaciclovir may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interactio... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.